Do you know how Swiss market access differs from the EU?
- Michael Zürcher
- Sep 2
- 1 min read
From regulatory approval to reimbursement, Switzerland follows its own rules, timelines and decision-making criteria. These can differ from EMA processes and EU market access pathways — and understanding those differences is key to success.
In the coming weeks, we will share short, practical posts that highlight the unique aspects of Swiss market access and what to keep in mind if you are used to EU processes.
Swizzard Pharma supports biotech and pharma companies in navigating these differences, offering hands-on expertise, tailored strategies and local knowledge to bring innovations to Swiss patients.
About Swizzard
Swizzard Pharma AG supports biotech and pharma companies in successfully entering and thriving in the Swiss market. Committed to bringing innovation to Switzerland, Swizzard helps clients maximize the value of their medical breakthroughs through expert market entry, preparation, commercialization and access strategies. With deep industry expertise, hands-on experience and an extensive network, Swizzard delivers fast, efficient, and tailored solutions. The company is led by CEO Michael Zürcher, a seasoned life sciences executive with a strong track record in the industry.
Comments